Breast cancer in pre-menopausal women in West Africa: Analysis of temporal trends and evaluation of risk factors associated with reproductive life

The Breast ◽  
2013 ◽  
Vol 22 (5) ◽  
pp. 828-835 ◽  
Author(s):  
Dominique Sighoko ◽  
Bakarou Kamaté ◽  
Cheick Traore ◽  
Brahima Mallé ◽  
Bourama Coulibaly ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
West Africa ◽  
Temporal Trends ◽  
Factors Associated ◽  
Menopausal Women ◽  
Reproductive Life

scholarly journals An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study

2021 ◽  
Vol 11 (3) ◽  
pp. 484-493
Author(s):  
Jukapun Yoodee ◽  
Aumkhae Sookprasert ◽  
Phitjira Sanguanboonyaphong ◽  
Suthan Chanthawong ◽  
Manit Seateaw ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Breast Cancer Patients ◽  
Ventricular Ejection Fraction ◽  
Factors Associated ◽  
Palliative Intent ◽  
Increased Risk

Anthracycline-based regimens with or without anti-human epidermal growth factor receptor (HER) 2 agents such as trastuzumab are effective in breast cancer treatment. Nevertheless, heart failure (HF) has become a significant side effect of these regimens. This study aimed to investigate the incidence and factors associated with HF in breast cancer patients treated with anthracyclines with or without trastuzumab. A retrospective cohort study was performed in patients with breast cancer who were treated with anthracyclines with or without trastuzumab between 1 January 2014 and 31 December 2018. The primary outcome was the incidence of HF. The secondary outcome was the risk factors associated with HF by using the univariable and multivariable cox-proportional hazard model. A total of 475 breast cancer patients were enrolled with a median follow-up time of 2.88 years (interquartile range (IQR), 1.59–3.93). The incidence of HF was 3.2%, corresponding to an incidence rate of 11.1 per 1000 person-years. The increased risk of HF was seen in patients receiving a combination of anthracycline and trastuzumab therapy, patients treated with radiotherapy or palliative-intent chemotherapy, and baseline left ventricular ejection fraction <65%, respectively. There were no statistically significant differences in other risk factors for HF, such as age, cardiovascular comorbidities, and cumulative doxorubicin dose. In conclusion, the incidence of HF was consistently high in patients receiving combination anthracyclines trastuzumab regimens. A reduced baseline left ventricular ejection fraction, radiotherapy, and palliative-intent chemotherapy were associated with an increased risk of HF. Intensive cardiac monitoring in breast cancer patients with an increased risk of HF should be advised to prevent undesired cardiac outcomes.

scholarly journals 82P Risk factors for breast cancer: A case-control study among post-menopausal women in Pakistan

2016 ◽  
Vol 27 ◽  
pp. ix24
Author(s):  
N.A. Jadoon ◽  
M. Hussain ◽  
F.U. Sulehri ◽  
A. Zafar ◽  
A. Ijaz
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Case Control Study ◽  
Case Control ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Control Study

Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: Systematic review and meta-analysis

2021 ◽  
pp. 100723
Author(s):  
George Koulaouzidis ◽  
Amanda E. Yung ◽  
Diana E. Yung ◽  
Karolina Skonieczna-Żydecka ◽  
Wojciech Marlicz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Systematic Review ◽  
Meta Analysis ◽  
Cardiac Risk ◽  
Factors Associated ◽  
Cardiac Risk Factors

scholarly journals Risk Factors Associated with Breast Cancer

2020 ◽  
pp. 1-3
Author(s):  
Victor Manuel Vargas-Hernandez
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Standard Deviation ◽  
Descriptive Analysis ◽  
Familial Risk ◽  
Breast Cancer Diagnosis ◽  
Graphical Analysis ◽  
Overweight And Obesity ◽  
Reproductive Life ◽  
Age Range

Background: It is reported that genetic and hereditary-familial risk factors for breast cancer contribute 5% and the majority are related to the reproductive life of women. Objective: it has the purpose of determining if the factors considered as risk factors are associated with breast cancer in a group of Mexican women. Material and Methods: A retrospective, observational and descriptive study was carried out in 162 women with breast cancer for 3 years (2002-2004) at the Hospital Juárez de México to determine if the usual risk factors are related to breast cancer. The descriptive analysis included localization and dispersion measures, as well as a graphical analysis using bar diagrams. Results: In the sample of 162 women with breast cancer, the age range at the time of breast cancer diagnosis was from 27 to 78 years (mean of 47.60, standard deviation of 13.09); early menarche only appeared in 12.3% (n=20). The mean age of the first pregnancy was 22 years and of menopause at 51 years of age; 72.2% lactated (n=117) and 45.1% did so for more than 6 months (n=73); the menstrual pattern disorder appeared in 22.8% of cases (n=37); Menopausal hormone therapy was previously used in 19.8% (n=32). The hereditary-family history of breast cancer appeared in 14.2% of the cases (n=23). It seems to be correlated with the fact that in patients with nulliparity, alcoholism and the absence of breastfeeding, breast cancer occurs at an early age (< 45 years) and the risk factor that is related to breast cancer is overweight and obesity with 54.26% and 17.11% respectively (average of 28.00, standard deviation of 3.032). Conclusion: no correlation was found between risk factors considered common for breast cancer; only overweight and obesity were related to its development, further research is required to confirm whether this correlation occurs in other countries.

scholarly journals Anemia Requiring Transfusion in Breast Cancer Patients on Dose-dense Chemotherapy: Prevalence, Risk Factors, Cost and Effect on Disease Outcome.

2021 ◽  
Author(s):  
Parth Sharma ◽  
Josh Thomas Georgy ◽  
Anand George Andrews ◽  
Ajoy Oommen John ◽  
Anjana Joel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Transfusion Requirement ◽  
Low Grade ◽  
Breast Cancer Patients ◽  
Factors Associated ◽  
Grade 3 ◽  
Dose Dense ◽  
Delay In Treatment

Abstract Purpose: Dose dense chemotherapy improves survival but also increases toxicity and treatment related cost. Here we report the prevalence of anemia, understand the risk factors of chemotherapy related anemia and determine the cost and time-delay associated with transfusion requirement in Indian non-metastatic breast cancer patients on dose dense preoperative chemotherapy.Methods: In this study, 116 triple negative breast cancer (TNBC) patients were treated preoperatively with Docetaxel and Cyclophosphamide alternating with Epirubicin and Cisplatin every 2-weekly. Patients were evaluated for anemia pre- and post-chemotherapy. We examined trends in the cell counts, transfusion requirement, time to transfusion as well as risk factors associated with transfusion during treatment, along with delay in treatment due to anemia and the additional cost incurred.Results: One hundred and sixteen women with high-risk non-metastatic TNBC were treated. Median age was 44.5 years. 56.1% had stage III disease. Delivery of 6/8 planned doses was achieved in 98.3% of patients, and all 8 doses in 86% patients. Anemia was detected at baseline in 54(46.5%) patients with mild(10-12g/dl) anemia in 42(36.2%) patients and moderate(8-10g/dl) in 12(10.3%) patients. Forty-four patients (37.9%) required transfusion during chemotherapy with 55(47.4%) patients having grade 1-2 anemia and 40(34.5%) patients having grade 3 anemia. The factors associated with transfusion were low grade of tumor (OR 2.48 (95% CI 1.08 - 5.68), p = 0.025), hemoglobin post 2 cycles of chemotherapy (OR 1.74 (95% CI 1.21- 2.51), p = 0.003), thrombocytopenia grade 3 or 4 (OR 4.35 (95% CI 1.062-17.827), p = 0.034) and drop in hemoglobin after 2 cycles (OR 1.65 (95% CI 1.09-2.48), p = 0.017). Nearly one fourth of the study population had a delay between two cycles of chemotherapy due to anemia. A median additional cost of Rs 7000 (IQR-Rs 7000 – Rs 14000) was incurred on transfusion.Conclusion: Anemia is a common toxicity associated with dose dense chemotherapy during curative breast cancer treatment leading to delay in treatment and increased cost. Low grade tumor, grade 3 or 4 thrombocytopenia and Grade 2 or higher anemia after 2 cycles of chemotherapy are risk factors for blood transfusions during treatment.

M277 RISK FACTORS ASSOCIATED WITH BREAST CANCER IN MEXICO

2012 ◽  
Vol 119 ◽  
pp. S621-S621
Author(s):  
G. Vega-Malagón ◽  
A.J. Vega-Malagón ◽  
A. Becerril-Santos ◽  
J.A. Rodriguez-Mendez ◽  
H.L. Hernandez-Montiel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Factors Associated

scholarly journals Temporal Trends and Risk Factors for Delayed Hospital Admission in Suspected Stroke Patients

2020 ◽  
Vol 9 (8) ◽  
pp. 2376
Author(s):  
Moritz Kielkopf ◽  
Thomas Meinel ◽  
Johannes Kaesmacher ◽  
Urs Fischer ◽  
Marcel Arnold ◽  
...  
Keyword(s):  
Risk Factors ◽  
General Practitioner ◽  
Time Delay ◽  
Emergency Medical Services ◽  
Symptom Onset ◽  
Temporal Trends ◽  
Medical Services ◽  
Factors Associated ◽  
Emergency Medical ◽  
Suspected Stroke

(1) Background: The benefit of acute ischemic stroke (AIS) treatment declines with any time delay until treatment. Hence, factors influencing the time from symptom onset to admission (TTA) are of utmost importance. This study aimed to assess temporal trends and risk factors for delays in TTA. (2) Methods: We included 1244 consecutive patients from 2015 to 2018 with suspected stroke presenting within 24 h after symptom onset registered in our prospective, pre-specified hospital database. Temporal trends were assessed by comparing with a cohort of a previous study in 2006. Factors associated with TTA were assessed by univariable and multivariable regression analysis. (3) Results: In 1244 patients (median [IQR] age 73 [60–82] years; 44% women), the median TTA was 96 min (IQR 66–164). The prehospital time delay reduced by 27% in the last 12 years and the rate of patients referred by Emergency medical services (EMS) increased from 17% to 51% and the TTA for admissions by General Practitioner (GP) declined from 244 to 207 min. Factors associated with a delay in TTA were stroke severity (beta−1.9; 95% CI–3.6 to −0.2 min per point NIHSS score), referral by General Practitioner (GP, beta +140 min, 95% CI 100–179), self-admission (+92 min, 95% CI 57–128) as compared to admission by emergency medical services (EMS) and symptom onset during nighttime (+57 min, 95% CI 30–85). Conclusions: Although TTA improved markedly since 2006, our data indicates that continuous efforts are mandatory to raise public awareness on the importance of fast hospital referral in patients with suspected stroke by directly informing EMS, avoiding contact of a GP, and maintaining high effort for fast transportation also in patients with milder symptoms.

scholarly journals ‘BRCA1’ RESPONSIVENESS TOWARDS BREAST CANCER-A POPULATION-WISE PHARMACOGENOMIC ANALYSIS

2016 ◽  
Vol 8 (9) ◽  
pp. 267 ◽  
Author(s):  
Preethi M. Iyer ◽  
Sanjay Kumar P. ◽  
Karthikeyan S. ◽  
P. K Krishnan Namboori
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
New Zealand ◽  
Environmental Factors ◽  
Chromosome 17 ◽  
Base Pairs ◽  
Single Nucleotide ◽  
Factors Associated ◽  
Variation Database ◽  
Different Populations

<p><strong>Objective: </strong>In the present pharmacogenomic work, the genetic, epigenetic and environmental factors associated with BRCA1 induced breast cancer, cancer proneness and its variants across different populations like Indian, Netherland, Belgium, Denmark, Austrian, New Zealand, Sweden, Malaysian and Norwegian and the ‘mutation and methylation-prone’ region of BRCA1 have been computed.</p><p><strong>Methods: </strong>The global variations associated with the disease have been identified from the ‘Leiden open variation database (LOVD 3.0)’ and ‘Indian genome variation database (IGVDB)’. The variants, ‘single nucleotide polymorphisms (SNPs)’ are then characterized. The epigenetic factors associated with breast cancer have been identified from the clinical reports and further scrutinized using EpiGRAPH tool. The various contributing environmental factors responsible for the variations have been considered.</p><p><strong>Results: </strong>All the variants across different populations such as Indian, Netherland, Belgium, Denmark, Austrian, New Zealand, Sweden, Malaysian and Norwegian are found to be in a specific transcript of BRCA1 that ranges within 41,196,312-41,277,500 (81,189 base pairs) of the chromosome 17. Two ‘single nucleotide variations (SNVs)’ (5266dupC: rs397507246 and 68_69delAG: rs386833395) have been identified as risk factors in hereditary breast and ovarian cancer syndrome in the global population and 39 SNPs have been identified as pathogenic and deleterious. ‘Evolutionary history’ seems to be the most significant attribute in the predictability of methylation of BRCA1. Unhealthy dietary habits, obesity, use of unsafe cosmetics, estrogen exposure, ‘hormone replacement therapy (HRT)’, use of oral contraceptives and smoking are the major environmental risk factors associated with breast cancer incidence.</p><p><strong>Conclusion: </strong>This chromosome location (41,196,312-41,277,500 (81,189 base pairs)) can be considered as the population-specific sensitive region corresponding to BRCA1 mutation. This supports the fact that stabilization within the region can be a promising technique to control the epigenetic variants associated with the global position. The global variation in the proneness of the disease may be due to a cumulative effect of genetic, epigenetic and environmental factors subject to further experimentations with identical variations and populations. </p>

Sign in / Sign up

Export Citation Format

Share Document